<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442026</url>
  </required_header>
  <id_info>
    <org_study_id>CT/06.11</org_study_id>
    <nct_id>NCT00442026</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC</brief_title>
  <official_title>A Multicenter Randomized Phase III Study of the Docetaxel and Gemcitabine Combination Versus Monotherapy With Gemcitabine as First-line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will compare the efficacy of the docetaxel and gemcitabine combination versus
      monotherapy with gemcitabine as first-line treatment in elderly patients with advanced NSCLC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Docetaxel and gemcitabine are well known active agents in the treatment of NSCLC. The
      standard treatment of elderly patients with advanced NSCLC is monotherapy with a third
      generation agent. However, there are only few randomized trials evaluating a two drug
      combination specifically addressed to elderly patients. The role of comprehensive geriatric
      assessment in treatment efficacy and tolerance is an area of investigation
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to poor accrual
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival between the two treatment arms</measure>
    <time_frame>Probability of 1 year survival (%)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Assessment every two cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>Assessment every two cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Non-small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically- or cytologically- confirmed Non-Small-Cell Lung Cancer

          -  Stage IIIB/IV

          -  No prior chemotherapy

          -  Presence of two-dimensional measurable disease. The measurable disease should not have
             been irradiated.

          -  Absence or irradiated and stable central nervous system metastatic disease

          -  Life expectancy of more than 3 months

          -  Age â‰¥ 70 years.

          -  Performance status (WHO) &lt; 3

          -  Patients &quot;non-frail&quot; according to comprehensive geriatric assessment

          -  Adequate bone marrow function (Absolute neutrophil count &gt; 1000/mm^3, Platelet count &gt;
             100000/mm^3, Hemoglobin &gt; 9gr/mm^3).

          -  Adequate liver (Bilirubin &lt; 1.5 times upper limit of normal and SGOT/SGPT &lt; 2 times
             upper limit of normal) and renal function (creatinine &lt; 2mg/dl).

          -  Adequate cardiac function (LVEF &gt; 50%).

          -  Informed consent.

        Exclusion Criteria:

          -  Psychiatric illness or social situation that would preclude study compliance.

          -  Other concurrent uncontrolled illness.

          -  Other invasive malignancy within the past 5 years except nonmelanoma skin cancer.

          -  No presence of a reliable care giver

          -  Other concurrent investigational agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lampros Vamvakas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete, Dep of Medical Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athanasios Karampeazis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dep of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Laikon&quot; General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>401 Military Hospital, Medical Oncology Unit</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Air Forces Military Hospital, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IASO&quot; General Hospital of Athens, 1st Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sotiria&quot; General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Metaxa's&quot; Anticancer Hospital of Piraeus,1st Dep of Medical Oncology</name>
      <address>
        <city>Piraeus</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theagenion&quot; Anticancer Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Elderly</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

